Sutro Biopharma (STRO) Cash from Financing Activities (2017 - 2025)
Sutro Biopharma (STRO) posted Cash from Financing Activities of -$64000.0 for Q4 2025, down 162.75% sequentially from $102000.0 in Q3 2025, and down 166.67% YoY from $96000.0 in Q4 2024.
Sutro Biopharma (STRO) Cash from Financing Activities (2017 - 2025) Analysis & Trends
Sutro Biopharma has reported Cash from Financing Activities for 9 years, with the latest figure at -$64000.0 in Q4 2025.
- Quarterly Cash from Financing Activities fell 166.67% year-over-year to -$64000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $44000.0 (down 99.95% YoY) and the FY2025 annual result came in at $44000.0, down 99.95% from the prior year.
- Cash from Financing Activities retreated to -$64000.0 in Q4 2025 per STRO's latest filing, from $102000.0 in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $137.7 million in Q2 2023 and troughed at -$5.7 million in Q3 2023.
- A 5-year average of $14.2 million and a median of $633000.0 in 2021 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2022 and 2025: Cash from Financing Activities jumped 14164.1% in 2022, then tumbled 166.67% in 2025.
- Over 5 years, Cash from Financing Activities stood at $506000.0 in 2021, then jumped by 2315.22% to $12.2 million in 2022, then slumped by 125.57% to -$3.1 million in 2023, then soared by 99.23% to -$24000.0 in 2024, then plunged by 166.67% to -$64000.0 in 2025.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered -$64000.0, $102000.0, and -$60000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.42 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -6.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -207,909.22 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -273.15 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.24 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 27.18 Mn |
| 10 | Sutro Biopharma | 339.58 Mn | 175.24 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -64,000.00 |
| Dec 31, 2025 | -64,000.00 |
| Sep 30, 2025 | 102,000.00 |
| Sep 30, 2025 | 102,000.00 |
| Jun 30, 2025 | -60,000.00 |
| Jun 30, 2025 | -60,000.00 |
| Mar 31, 2025 | 66,000.00 |
| Mar 31, 2025 | 66,000.00 |
| Dec 31, 2024 | -24,000.00 |
| Dec 31, 2024 | -24,000.00 |
| Sep 30, 2024 | 1.02 Mn |
| Sep 30, 2024 | 1.02 Mn |
| Jun 30, 2024 | 96.49 Mn |
| Jun 30, 2024 | 96.49 Mn |
| Mar 31, 2024 | -3.43 Mn |
| Mar 31, 2024 | -3.43 Mn |
| Dec 31, 2023 | -3.13 Mn |
| Dec 31, 2023 | -3.13 Mn |
| Sep 30, 2023 | -5.74 Mn |
| Sep 30, 2023 | -5.74 Mn |